Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Different Doses of Olmesartan Medoxomil Compared to Losartan on Proteinuria, Renal Function and Inflammatory Markers in Type 2 Diabetics With Nephropathy

NCT00362960 is registered in ClinicalTrials.gov with Sankyo Pharma Gmbh as lead sponsor.

NCT NCT00362960
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00362960 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Different Doses of Olmesartan Medoxomil Compared to Losartan on Proteinuria, Renal Function and Inflammatory Markers in Type 2 Diabetics With Nephropathy
Lead sponsor
Sankyo Pharma Gmbh
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2003
Completion date
September 30, 2004
Enrollment
300
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic nephropathy, proteinuria, renal disease, type 2 diabetes mellitus